Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EBITDA: 2017-2025

Historic EBITDA for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to $20.7 million.

  • Organogenesis Holdings' EBITDA rose 232.06% to $20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year increase of 34.41%. This contributed to the annual value of -$1.3 million for FY2024, which is 110.24% down from last year.
  • According to the latest figures from Q3 2025, Organogenesis Holdings' EBITDA is $20.7 million, which was up 264.81% from -$12.6 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' EBITDA ranged from a high of $23.6 million in Q2 2021 and a low of -$26.7 million during Q1 2025.
  • For the 3-year period, Organogenesis Holdings' EBITDA averaged around -$668,455, with its median value being -$1.3 million (2023).
  • As far as peak fluctuations go, Organogenesis Holdings' EBITDA spiked by 1,147.38% in 2021, and later crashed by 3,025.78% in 2023.
  • Over the past 5 years, Organogenesis Holdings' EBITDA (Quarterly) stood at $19.8 million in 2021, then crashed by 55.86% to $8.7 million in 2022, then plummeted by 114.56% to -$1.3 million in 2023, then spiked by 905.28% to $10.2 million in 2024, then soared by 232.06% to $20.7 million in 2025.
  • Its EBITDA stands at $20.7 million for Q3 2025, versus -$12.6 million for Q2 2025 and -$26.7 million for Q1 2025.